10.1038/s41598-021-97967-0 Summary Keywords heart failure, GLP-1, glucagon-like peptide-1, clinical trials, cardiovascular disease, cardiovascular outcome studies, diabetes, obesity Citation Kreiner FF, Hovingh GKK and von Scholten BJ (2022) The potential of glucagon-like peptide-1 receptor agonists in heart failure
Moreover, IL-6/STAT3 activation can impair innate antitumor immunity by suppressing the activity of NK cells [175]
Westphal, then working at a Boston venture capital firm, approached Dr
Phospholipid bilayers in the liquid crystalline state are preferred for transdermal drug administration, and liposomal formulations depending on composition may be divided into two major groups: innovative liposomes such as flexible/deformable/elastic liposomes and standard liposomes [307]